Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579211 | 1.00 | PARP1 (0.38) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL1033901 | 1.00 | PARP1 (0.38) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL29264141 | 0.89 | NPC1 (0.36) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL652904 | 0.89 | NPC1 (0.36) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL652905 | 0.89 | NPC1 (0.36) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL652903 | 0.89 | NPC1 (0.36) | PARP1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL20136819 | 0.85 | SLC6A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20744262 | 0.85 | SLC6A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20744258 | 0.85 | SLC6A1 (0.36) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1470518 | 0.85 | SLC6A1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-109415371-B | 2-amido thiazole derivative and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20190315771-A1 | NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| EP-3511332-A1 | NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-07-17 | — | — | EP | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | PARP1 4244/4885HTR2A 1259/4885HTR2C 940/4885 |
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | PARP1 1221/4885HTR2A 1226/4885HTR2C 1030/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | PARP1 1067/4885HTR2A 4135/4885HTR2C 3513/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | PARP1 4042/4885HTR2A 1346/4885HTR2C 969/4885 |
| US-20190315771-A1 | NOVEL 2-ACYLAMINOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | TEK, MPL, THPO | PARP1 2632/4885HTR2A 2001/4885HTR2C 1195/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | PARP1 1111/4885HTR2A 150/4885HTR2C 106/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | PARP1 4244/4885HTR2A 1259/4885HTR2C 940/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | PARP1 4042/4885HTR2A 1346/4885HTR2C 969/4885 |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | PARP1 1236/4885HTR2A 4581/4885HTR2C 4235/4885 |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | PARP1 1102/4885HTR2A 4637/4885HTR2C 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.